Related Experiment Videos
Human tumor antigens recognized by T-cells
1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA. yutakawa@nih.gov
Immunologic Research
|January 1, 1997
Summary
T-cells are crucial for tumor rejection. Identifying tumor antigens and using immunotherapies are key to developing new cancer treatments.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- T-cells are vital in rejecting tumors in animal models and human melanoma.
- Numerous human tumor antigens, derived from self or viral proteins, have been identified.
- Mechanisms generating T-cell epitopes on cancers are increasingly understood.
Purpose of the Study:
- To evaluate the role of identified tumor antigens in cancer rejection.
- To assess the efficacy of passive or active immunotherapies targeting these antigens.
- To inform the development of novel antigen-specific cancer immunotherapies.
Main Methods:
- Identification of tumor antigens recognized by autologous T-cells.
- Analysis of mechanisms generating T-cell epitopes on cancer cells.
- Conducting clinical trials for passive or active immunotherapy.
Main Results:
- Many tumor antigens (mutated and nonmutated peptides) have been identified.
- Mechanisms for T-cell epitope generation on cancers are elucidated.
- Clinical trials using identified tumor antigens are underway.
Conclusions:
- Further evaluation of identified antigens is necessary.
- Clinical trial results will clarify the role of T-cell responses in tumor rejection.
- Antigen-specific immunotherapies hold promise for cancer treatment.